Disagree
Home Dragon Pharma Dragon Pharma
IGF-1 LR3
IGF-1 LR3 - Dragon Pharma

IGF-1 LR3 - Dragon Pharma

Brand:
Category:
Substance:
Package:
1 mg
Price:
$75.00 - $130.00
See options
Product Overview

In 1992 Long(R3)-IGF-1 was introduced as a modified version of IGF1 with the aim to prolong the peptides life and improve its ability to resist proteins for better effectiveness, in promoting muscle growth through its anabolic and catabolic properties. These modifications allow Long(R3)-IGF-1 to have 2.5 to 3 times the potency of regular IGF-1, making it a popular choice in muscle-building circles

References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about IGF-1 LR3 by Dragon Pharma, consult with your doctor or healthcare professional.

Products
Show more
Explore More Products
FAQ
What is Long(R3)-IGF-1?
Long R3, IGF1 one is a man made version of Insulin Like Growth Factor I (IGF1). Its produced by altering the IGF I protein. By including 13 amino acids and changing an arginine at the third position. This modification increases its potency and resistance to binding proteins, making it 2.5 to 3 times stronger than natural IGF-I​​.
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

When was Long(R3)-IGF-1 first synthesized?
Long(R3)-IGF-1 was first described in 1992 by Francis et al. It was created as one of IGF I analogues specifically crafted for use, in research settings to enhance the study of IGF I functions during experiments.
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.

How does Long(R3)-IGF-1 differ from regular IGF-I?
Long(R3)-IGF-1 differs from regular IGF-I in that it has a longer half-life and is less prone to binding with proteins that inhibit IGF-I. Additionally, it can have lipogenic properties, unlike regular IGF-I, meaning it may increase fat gain rather than fat loss in some users.
References:

Llewellyn, W. (2017). William Llewellyn's Anabolics.
United States: Molecular Nutrition, LLC.